Business Context and Reporting Period
This Form 6-K filing by AC Immune SA covers the month of April 2018, specifically reporting the results of an Extraordinary General Meeting held on April 27, 2018. The company is a foreign private issuer based in Lausanne, Switzerland.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance actions and capital structure changes approved by shareholders.
Material Changes
- Board Composition: Shareholders approved the election of Douglas Williams as a new member of the Board of Directors and the Compensation, Nomination & Corporate Governance Committee.
- Executive Compensation: Shareholders approved additional compensation for the new board member for the period of April 27, 2018, to June 30, 2018, consisting of up to CHF 11,800 in cash and up to CHF 76,000 in equity or equity-linked instruments.
- Share Capital Increase: Shareholders authorized two distinct share capital increases:
- Institutional Investors: An increase of up to CHF 170,000 via the issuance of up to 8,500,000 registered shares (nominal value CHF 0.02 each).
- Current Shareholders: An increase of up to CHF 30,000 via the issuance of up to 1,500,000 registered shares (nominal value CHF 0.02 each), with pre-emptive rights preserved.
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, or specific risk factors. It notes that the Board of Directors is authorized to determine the technical issuance price for the new shares and that the new shares are subject to transfer restrictions outlined in the Articles of Association. The Board is instructed to implement and register the capital increases with the competent commercial register.
Investor Verification Checklist
- Verify the final subscription price and total capital raised from the institutional and current shareholder offerings.
- Confirm the exact number of shares issued and the resulting total share count post-capital increase.
- Review the specific terms of the equity grant awarded to Douglas Williams.
- Check subsequent filings for the official registration of the capital increase with Swiss commercial authorities.